In the case of pregnant women presenting heterozygous loss-of-function mutations and an unaffected child, the increased insulin secretion and insulin-stimulated growth secondary to maternal hyperglycemia can increase the risk of fetal macrosomia. The gene discussed is INS; the disease is Hyperglycemia.